// App-Quantinova.ai

Su1396 : Crohn's Disease Outpatients Treated With Adalimumab Have an Earlier Loss of Response and Requirement for Dose Intensification Compared to Infliximab

Researchers

Presenter

  • Vivian Huang

Principal Investigators

  • Darryl K. Fedorak

  • Karen I. Kroeker

  • Levinus A. Dieleman

  • Richard N. Fedorak

Medical Centers

  • Division of Hematology, University of Alberta, Edmonton, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Anal fistula

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Oraprine

  • Methotrexate

  • Adalimumab

  • Infliximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved